Wockhardt introduces Glaritus in India
and biotechnology company Wockhardt has launched its new insulin (Glaritus),
a recombinant long acting human insulin analogue. The product is the biosimilar
of a glargine insulin marketed by Sanofi-Aventis under the brand name Lantus,
Currently, the worldwide market of glargine insulin is $2 billion. As per ORG
IMS estimates, the current market for insulin analogues in India is Rs 120 crore
and it is growing at 37 percent per annum.
Glaritus has been clinically tested on 300 diabetic patients for safety and
efficacy parameters and is approved by the Drug Controller General, (India)
(DCGI). As per a company press release, Wockhardt is the first company in the
world after the innovator (Sanofi-Aventis) to launch an insulin analogue that
works slowly over a 24 hour period. Glaritus is manufactured at Wockhardt's
state-of-the-art biotech park in Aurangabad. It is available to patients as
reusable and disposable pen delivery devices.
"Back in 2003, when I promised that we would launch Glaritus, the world's
most advanced insulin, there was disbelief all around. Today, the world will
look at India in admiration. The nation's biotech prowess would once again be
a global talking point," said Wockhardt Chairman Habil Khorakiwala.
The launch of Glaritus is a significant landmark for India, which has one of
the highest diabetes affected populations in the world. The advantage of Glaritus
is that it is a once daily dose and provides basal glucose control over 24 hours.
Glaritus can hence be easily combined with other oral medications of diabetes
for effective blood glucose control. Moreover, Glaritus is a meal independent,
peak less insulin, which reduces incidences of hypoglycaemia significantly.
All this translates into more compliance to insulin therapy, improved blood
glucose control and therefore slower progression of diabetes related complications.
"Wockhardt becomes the first company in the biotechnology space to move
from simple biologicals to complex biologicals with vast experience in both,
E.coli and Yeast platforms," he further added. Wockhardt has built a comprehensive
diabetes management portfolio that includes insulins, oral medications, blood
glucose monitors and diabetes nutrition products.